Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 4;33(9):1331-1344.
doi: 10.1136/ijgc-2023-004610.

Low-grade serous ovarian cancer: expert consensus report on the state of the science

Rachel N Grisham  1 , Brian M Slomovitz  2   3 , Nicole Andrews  4 , Susana Banerjee  5 , Jubilee Brown  6 , Mark S Carey  7 , Herman Chui  8 , Robert L Coleman  9 , Amanda N Fader  10 , Stephanie Gaillard  10 , Charlie Gourley  11 , Anil K Sood  12 , Bradley J Monk  13 , Kathleen N Moore  14 , Isabelle Ray-Coquard  15   16 , Ie-Ming Shih  10 , Shannon N Westin  12 , Kwong-Kwok Wong  12 , David M Gershenson  12
Affiliations

Low-grade serous ovarian cancer: expert consensus report on the state of the science

Rachel N Grisham et al. Int J Gynecol Cancer. .

Abstract

Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel-presented in this consensus document-will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.

Keywords: Cystadenocarcinoma, Serous; Ovarian Cancer; Pathology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RG reports fees for grants/contracts from Context Therapeutics, Versatem, SpringWorks, Bayer, Novartis; fees for consulting for GSK, AstraZeneca, Natera, Corcept, Intellisphere, SpringWorks, Verastem, Myriad; fees for payment/honoraria from Prime Oncology, MCM Education, OncLive, Aptitude Health, Cardinal Health; fees for leadership/ fiduciary role with NCCN Ovarian Cancer Guidelines Committee Member, and ICLC Precision Therapeutics. BS reports consulting fees for AstraZeneca, Clovis, GSK, Genentech, Onconova, Nuvation, Lilly, EQRx, Myriad, Immunogen, Novocure, and Merck. NA has no conflicts to disclose. SB reports fees for grants/contracts from AstraZeneca, GSK; fees for consulting for AstraZeneca, GSK, Immunogen, Merck Sharpe Dohme, EMD/Merck Serono, Mersana, Novartis, Oncxerna, Seagen, Shattuck Labs, Regeneron, Epsilogen; fees for payment/honoraria from Amgen, AstraZeneca, Clovis, GSK, Immunogen, Merck Sharpe Dohme, Mersana, Pfizer, Roche, Takeda, Novacure; fees for support for attending meetings/travel from AstraZeneca, GSK, Verastem; fees for leadership/fiduciary role from ESMO Director of Membership (2020-2022); and fees for other financial or non-financial interests from Global PI ENGOTov60/GOG3052/RAMP201. JB reports fees for consulting for Caris Life Sciences, AstraZeneca, Verastem, Genentech, GSK Tesaro; fees for participation on a Data Safety Monitoring Board/Advisory Board from Caris, AstraZeneca, GSK Tesaro, Verastem; fees for a leadership/fiduciary role from American Association of Gynecologic Laparoscopy, and Society of Gynecologic Oncology. MSC reports fees for grants/contracts from Canada Research Society, Canadian Institute for Health Research, Ovarian Cancer Canada, BC Cancer Foundation, Department of Defense US Army, Australian Medical Research Fund; fees for payment/honoraria from Verastem; fees for leadership/fiduciary role from Canadian Cancer Trials Group; and fees for stock or stock option from Bausch Health Companies, Illumina, aiGENE, DentalToday, Hexamer Therapeutics. HC reports fees for payment/honoraria from Verastem Oncology. RLC reports fees for grants/contracts from AstraZeneca, Clovis, Genelux, Genmab, Merck, Immunogen, Roche/Genentech; consulting fees from Agenus, Alkermes, AstraZeneca, Clovis, Deciphera, Genelux, Genmab, GSK, Immunogen, OncoQuest, Onxerna, Regeneron, Roche/Genentech, Novocure, Merck, Abbvie; fees for payment/honoraria from AstraZeneca, Clovis, Roche/Genentech, Merck; fees for participation on a Data Safety Monitoring Board/Advisory Board from VBL Therapeutics, and Eisai/BMS. ANF reports fees for advisory board support from Versatem and PI of the NCI NRG GY019. SG reports fees for patents for United States Patent Nos 10,258,604 & 10,905,659; and fees for participation on a Data Safety Monitoring Board/Advisory Board from Verastem. CG reports fees for grants from AstraZeneca, GSK, Tesaro, Clovis, MSD, BergenBio, Novartis, Aprea, Nucana, Versatem, Roche, Medannexin; fees for consulting from AstraZeneca, MSD, GSK, Tesaro; fees for payment/honoraria from AstraZeneca, MSD, GSK, Tesaro, Clovis, Roche, Nucana, Chugai, Takeda, Cor2Ed, Peervoice; fees for participation on a Data Safety Monitoring Board/Advisory Board from AstraZeneca, MSD, GSK, Tesaro, Roche, Nucana, Chugai; and fees for a leadership/fiduciary role from Scottish Medicines Consortium. AKS reports fees for grants from American Cancer Society Research Professor Award; fees for royalties from EGFL6 antibody; fees for consulting for Merck, GSK, Iylon, ImmunoGen, Onxeo, Kiyatec; fees for leadership/fiduciary role from SGO Board of Directors; and fees from stock/stock options for BioPath. BJM reports fees for consulting for Acrivon, Adaptimune, Agenus, Akeso Bio, Amgen, Aravive, AstraZeneca, Bayer, Clovis, Eisai, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, Heng Rui, ImmunoGen, Karyopharm, Iovance, Laekna, Macrogenics, Merck, Mersana, Myriad, Novartis, Novocure, OncoC4, Panavance, Pieris, Pfizer, Puma, Regeneron, Roche/Genentech, Sorrento, Tesaro/GSK, US Oncology Research, VBL, Verastem, Zentalis; fees for payment/honoraria from AstraZeneca, Clovis, Easai, Merck, Myriad, Roche/Genentech, and Tesaro/GSK. KNM reports fees for grants/contracts and participation on a data safety monitoring board from PTC Therapeutics, Lilly, Clovis, Genentech, GSK, Verastem; fees for consulting for AstraZeneca, Aravive, Alkemeres, Addi, Blueprint pharma, Clovis, Eisai, GSK, Genentech/Roche, Hengrui, Immunogen, Inxmed, IMab, Iovance, Lilly, Mereo, Mersana, Merck, Myriad, Norvartis, Novocur, OncXerna, Onconova, Tarveda, VBL Therapeutics, Verastem; fees for payment/honoraria from AstraZeneca, GSK, Immunogen, PRIME, RTP, Medscape, Great Debates and Updates; fees for support for attending meetings/travel from AstraZeneca; and a leadership/fiduciary role with GOG P Associate Director. IRC reports fees for grants/contracts from MSH, Roche, BMS, Novartis, AstraZeneca, Merck, Sereno; fees for consulting for Agenus, Amgen, BMS, AstraZeneca, Roche, GSK, Deciphera, Mersena, Novartis, Clovis, Adaptimmun, DAICHI Sankyo, Immunogen, Blueprint; fees for support for attending meetings/travel from OSE Company (ASCO 2022); fees for participation on a Data Safety Monitoring Board or Advisory Board from Athena trial, Attend trial and AGO-OVAR57 trial. IMS has no conflicts of interest. SNW reports fees for grants/contracts from AstraZeneca, Bayer, Clovis Oncology, AvengeBio, GSK, Mereo, Novartis, Bio-Path, Roche/Genentech, Zentalis; fees for consulting for ZielBio, AstraZeneca, Clovis Oncology, Eisai, Merck, Mereo, Mersana, Seagen, Nuvectis, Verastem, EQRx, GSK, Immunogen, Lilly, Zentalis, Roche/Genentech, Caris, Vincerx, and NGM Bio. KKW reports fees for support for the present manuscript from MD Anderson Ovarian Cancer Moon Shot Program, STAAR Ovarian Cancer Foundation, The Ludemann Family, and Department of Defense Grant (W81XWH-19-1-0169). DG reports fees for support for the present manuscript from Verastem; fees for grants/contracts from National Cancer Institute, Novartis; fees for royalties/licenses from Elsevier, UpToDate; fees for consulting for Genentech, Verastem; fees for payment/honoraria from University of Washington Grand Rounds, Yale University School of Medicine Grand Rounds; fees for support for attending meetings/travel from Society of Gynecologic Oncology Bridges Program, Verastem; fees for participation on a Data Safety Monitoring Board or Advisory Board from Verastem, Aadi, Onconova; fees for leadership/fiduciary role from Chair, International Consortium of Low-Grade Serious Ovarian Cancer; and fees for stock/stock options from J&J, BMS, and Procter and Gamble.

Comment in

References

    1. Matsuo K, Machida H, Grubbs BH, et al. . Trends of low-grade Serous ovarian carcinoma in the United States. J Gynecol Oncol 2018;29:e15. 10.3802/jgo.2018.29.e15 - DOI - PMC - PubMed
    1. Bodurka DC, Deavers MT, Tian C, et al. . Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group study. Cancer 2012;118:3087–94. 10.1002/cncr.26618 - DOI - PMC - PubMed
    1. Plaxe SC. Epidemiology of low-grade Serous ovarian cancer. Am J Obstet Gynecol 2008;198:459. 10.1016/j.ajog.2008.01.035 - DOI - PubMed
    1. Gockley A, Melamed A, Bregar AJ, et al. . Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol 2017;129:439–47. 10.1097/AOG.0000000000001867 - DOI - PMC - PubMed
    1. Slomovitz B, Gourley C, Carey MS, et al. . Low-grade serous ovarian cancer: state of the science. Gynecol Oncol 2020;156:715–25. 10.1016/j.ygyno.2019.12.033 - DOI - PubMed

Publication types